← Back to patent-cliff list
苯磺酸氨氯地平/坎地沙坦酯
Tier C — Watch / tradeAmlodipine Besylate/Candesartan Cilexetil
武田药品工业株式会社
Originator
2010
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：AT1、VDCCs
Brand：Unisia、Cantabell
Indications (approved)：高血压
Regional status
US
-
EU
-
China
临床三期
2024-09-26
Japan
批准上市
2010-04-06
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amlodipine Besylate/Candesartan Cilexetil?
Approved indications include: 高血压.
When does the Amlodipine Besylate/Candesartan Cilexetil patent expire?
No public expiry year is available for Amlodipine Besylate/Candesartan Cilexetil yet; this page updates once verified.
How do I get a quote for Amlodipine Besylate/Candesartan Cilexetil intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24